F182112 study for people with lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests a new drug called F182112 for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. The drug targets certain immune cells to possibly reduce lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lupus for at least 12 weeks.
- You have not had BCMA-targeted therapy before.
- You have not had B-cell depletion therapy (like anti-CD20 or anti-CD19) or anti-plasma cell therapy in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study tests a new investigational drug called SCTC21C for people with moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can help control lupus symptoms and reduce disease activity.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Hear when a new Systemic Lupus Erythematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.